2m 2m 2m 2m 2m 2m 2m
Alpha Tau Med (DRTS)
NASDAQ
$9.95-$0.08 (-0.85%)
Price as of Jun 23, 2026 5:57 PM EDT- $334.4MMarket Cap
- 236.01%1-Year Change
- BiotechnologyIndustry
Alpha Tau Med (DRTS)
$9.95-$0.08 (-0.85%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | 1.9M -20.82% | 2.3M +22.09% | 1.9M +97.54% | 974,000 +102.07% | |
Research and Development Expense | -32.1M +18.67% | -27.0M +2.26% | -26.4M +26.49% | -20.9M +82.49% | |
Depreciation and Amortization Expense | 1.2M +11.80% | 1.1M +2.61% | 1.1M +9.70% | 979,000 +26.16% | |
Total Operating Expenses | 8.4M +25.33% | 6.7M -8.99% | 7.3M -28.62% | 10.3M +451.96% | |
Operating Profit | -42.3M +17.33% | -36.0M +1.01% | -35.7M +11.03% | -32.1M -333.04% | |
Interest Income | 3.8M -10.29% | 4.3M -11.45% | 4.8M +169.83% | 1.8M +748.34% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 3.8M -10.29% | 4.3M -11.45% | 4.8M +169.83% | 1.8M +748.34% | |
Total Nonoperating Income and Expense | -218,000 -105.07% | 4.3M -34.27% | 6.5M +507.16% | -1.6M -111.92% | |
Income before Taxes | -42.5M +33.90% | -31.7M +8.93% | -29.1M -13.64% | -33.7M -223.76% | |
Income Taxes | 121,000 +1,916.67% | 6,000 -62.50% | 16,000 -20.00% | 20,000 +385.71% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -42.6M +34.26% | -31.8M +8.89% | -29.2M -13.64% | -33.8M +23.80% | |
Net Income from Continuing Operations Applicable to Common | -42.5M +33.90% | -31.7M +8.93% | -29.1M -13.64% | -33.7M -223.76% | |
Basic EPS and Net Income | -0.53 +17.78% | -0.45 +7.14% | -0.42 -20.75% | -0.53 -20.90% | |
Diluted EPS and Net Income | -0.53 +17.78% | -0.45 +7.14% | -0.42 -20.75% | -0.53 -20.90% | |
Basic Weighted Average Shares | 80.6M +15.24% | 69.9M +0.79% | 69.4M +9.20% | 63.5M +56.74% | |
Diluted Weighted Average Shares | 80.6M +15.24% | 69.9M +0.79% | 69.4M +9.20% | 63.5M +56.74% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 12.2M -11.09% | 13.7M +8.43% | 12.7M +116.88% | 5.8M -74.88% | |
Short-Term Investments | 60.9M +32.80% | 45.9M -33.64% | 69.1M -29.95% | 98.7M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 73.1M +22.69% | 59.6M -27.13% | 81.8M -21.76% | 104.5M +349.86% | |
Total Current Assets | 78.3M +21.90% | 64.2M -25.10% | 85.8M -19.46% | 106.5M +226.21% | |
Accumulated Depreciation | 5.3M +30.10% | 4.1M +36.69% | 3.0M +56.80% | 1.9M +107.35% | |
Property and Plant and Equipment and Net | 19.7M +41.10% | 13.9M +8.88% | 12.8M +71.30% | 7.5M -0.99% | |
Total Long-Term Assets | 27.4M +24.48% | 22.0M +1.59% | 21.6M +58.22% | 13.7M +42.80% | |
Total Assets | 105.7M +22.56% | 86.2M -19.73% | 107.4M -10.62% | 120.1M +184.61% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 10.5M +21.12% | 8.7M +22.15% | 7.1M +63.72% | 4.3M -1.52% | |
Total Long-Term Debt | 6.4M +14.22% | 5.6M -0.87% | 5.6M N/A | N/A N/A | |
Total Long-Term Liabilities | 18.0M +21.42% | 14.9M -6.00% | 15.8M +55.71% | 10.2M -45.48% | |
Total Liabilities | 28.6M +21.31% | 23.5M +2.73% | 22.9M +58.11% | 14.5M -37.07% | |
Retained Earnings | -190.1M +28.90% | -147.5M +27.43% | -115.8M +33.67% | -86.6M +63.89% | |
Total Stockholders Equity | 77.1M +23.03% | 62.7M -25.82% | 84.5M -20.05% | 105.7M +403.81% | |
Total Shares Outstanding | 88.0M +25.05% | 70.4M +1.02% | 69.7M +0.82% | 69.1M +70.51% | |
Cash Flow | |||||
Cash from Operating Activities | -26.7M +34.87% | -19.8M +10.16% | -18.0M -24.80% | -23.9M +102.16% | |
Capital Expenditures | 6.1M +171.45% | 2.2M -65.04% | 6.4M +608.08% | 904,000 -69.12% | |
Cash from Investing Activities | -20.6M -199.13% | 20.8M +11.17% | 18.7M +120.77% | -89.9M -566.64% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 45.8M +182,972.00% | 25,000 -99.53% | 5.3M -94.53% | 96.9M +87,201.80% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -44.44% +35.47% | -32.80% +27.99% | -25.63% -38.38% | -41.59% N/A | |
Return on Equity | -61.00% +41.34% | -43.16% +40.71% | -30.67% -67.81% | -95.27% N/A | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 7.45 +0.65% | 7.40 -38.68% | 12.07 -50.81% | 24.55 N/A | |
Cash Ratio | 1.16 -26.59% | 1.58 -11.23% | 1.78 +32.48% | 1.35 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow